{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:16:36Z","timestamp":1792196196496,"version":"4.4.0"},"reference-count":65,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T00:00:00Z","timestamp":1756252800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["24K09962"],"award-info":[{"award-number":["24K09962"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Chemotherapy\u2010induced neutropenia (CIN) and febrile neutropenia (FN) are important considerations for anticancer drug dosing. Recent studies suggest that CIN may also improve survival. This study aimed to assess the impact of CIN on survival outcomes in breast cancer patients and to develop a predictive model for CIN incorporating genetic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In 166 breast cancer patients treated with doxorubicin and cyclophosphamide (AC therapy), neutropenia was classified into three severity groups using CTCAE v5.0 criteria. The relationship between severe CIN and survival was analysed. Additionally, 33 genetic polymorphisms linked to pharmacokinetics and susceptibility were examined, and a predictive model for CIN was built using multivariate logistic regression integrating clinical and genetic factors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients receiving AC therapy, the 10\u2010year survival rates were 80.6% for the Grades 0\u20132 group, 96.2% for the Grades 3\u20134 group without FN, and 79.0% for the Grades 3\u20134 group with FN, indicating that patients in the Grades 3\u20134 group without FN had significantly longer survival. A predictive model for Grade 4 CIN was developed using seven factors: age, haemoglobin levels, serum creatinine levels, and the genetic polymorphisms\n                      <jats:italic>ABCB1<\/jats:italic>\n                      rs1128503,\n                      <jats:italic>ERCC1<\/jats:italic>\n                      rs11615,\n                      <jats:italic>ERCC2<\/jats:italic>\n                      rs238406 and\n                      <jats:italic>XRCC3<\/jats:italic>\n                      rs709399. The model had an AUC of 0.744 (95% CI, 0.666\u20130.823), and including genetic polymorphisms improved predictive accuracy by 0.128 (\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.004).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CIN was linked to improved survival in breast cancer patients. The predictive model including genetic factors provided a more accurate assessment of CIN risk, potentially enabling more personalized treatment approaches.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70259","type":"journal-article","created":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:06:56Z","timestamp":1756285616000},"page":"230-245","source":"Crossref","is-referenced-by-count":1,"title":["Development of a predictive model for neutropenia risk in Japanese breast cancer patients treated with doxorubicin and cyclophosphamide"],"prefix":"10.1002","volume":"92","author":[{"given":"Takehiro","family":"Miyagi","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences University of Shizuoka  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8894-2841","authenticated-orcid":false,"given":"Daiki","family":"Tsuji","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences University of Shizuoka  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nakatani","sequence":"additional","affiliation":[{"name":"Department of Biostatistics and Health Data Science Graduate School of Medical Science Nagoya City University  Nagoya Japan"},{"name":"Graduate School of Public Health Shizuoka Graduate University of Public Health  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Sahara\u2010Ishino","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences University of Shizuoka  Shizuoka Japan"},{"name":"Department of Pharmacy Seirei Hamamatsu General Hospital  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chika","family":"Kodama","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences University of Shizuoka  Shizuoka Japan"},{"name":"Ain Pharmacy Nippon Medical School Musashi Kosugi Hospital  Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umi","family":"Tokou","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Seirei Hamamatsu General Hospital  Hamamatsu Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Itoh","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology &amp; Genetics, School of Pharmaceutical Sciences University of Shizuoka  Shizuoka Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,8,27]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.21.4791"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq683"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8793"},{"issue":"8","key":"e_1_2_11_6_1","first-page":"1261","article-title":"Pharmacokinetic interrelationships of irinotecan (CPT\u201011) and its three major plasma metabolites in patients enrolled in phase I\/II trials","volume":"3","author":"Rivory LP","year":"1997","journal-title":"Clin Cancer Res"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.06.027"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDG019"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.09.102"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228\u2010017\u20102260\u20100"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00228\u2010023\u201003451\u20101"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601366"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0168519"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0090\u20109556(25)05924\u20100"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.108.024711"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.113.206805"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349\u20107006.2008.00903.x"},{"issue":"23","key":"e_1_2_11_18_1","first-page":"5629","article-title":"Differential activation of cyclophosphamide and ifosphamide by cytochromes P\u2010450 2B and 3A in human liver microsomes","volume":"53","author":"Chang TKH","year":"1993","journal-title":"Cancer Res"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/BIOTECH13010003"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/S42764\u2010020\u201000026\u20107"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201011\u20100761\/84419\/AM\/DNA\u2010REPAIR\u2010FROM\u2010GENOME\u2010MAINTENANCE\u2010TO\u2010BIOMARKER"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2009.09.006"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201004\u20102216"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201004\u20100247"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/S00280\u2010020\u201004177\u2010Y"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010012\u20101345\u20105"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097\u20100142(20000215)88:4<796::AID\u2010CNCR10>3.0.CO;2\u2010P"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.244"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15542"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/BPH.15543"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.CTRV.2022.102427"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/J.EJCA.2010.10.013"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.25691"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.1634\/THEONCOLOGIST.10\u20106\u2010427"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.6004\/JNCCN.2022.0026"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/CNCR.25332"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/ONCO.13822"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000366466"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.122"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349\u20107006.2008.00744.x"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2018.4583"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clcc.2011.03.024"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349\u20107006.2008.01031.x"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15565"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.22034\/APJCP.2017.18.2.507"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1186\/1756\u20109966\u201031\u201025"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586\u2010023\u201005959\u2010z"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep06281"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00206"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078\u20100432.CCR\u201008\u20102715"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2004.10.032"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/22.6.899"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90\u20104\u20101614"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/JGM.3266"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1159\/000477109"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.18632\/ONCOTARGET.9146"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/2976373"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejm197602192940801"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.929"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.6004\/JNCCN.2020.0002"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1093\/ANNONC\/MDW325"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.3488"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10549\u2010008\u20100018\u20101"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.6004\/JNCCN.2023.7070"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/S10585\u2010018\u20109917\u20107"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.3390\/PH13110406"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70259","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70259","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70259","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T05:35:57Z","timestamp":1769146557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70259"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,27]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/bcp.70259"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70259","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,27]]}}}